|
||||||||||||
CME Information
|
|
|
|
Course Overview |
At the 2nd International Consultation on Sexual Medicine held in
Educational Objectives |
At the conclusion of this activity, the participant should be able to:
Describe the female sexual response cycle
Describe the key factors influencing female sexual function
Identify the classifications of FSD
Describe the potential role of sex hormones, estrogen and testosterone in female sexual function
Target Audience |
back to top |
This CME activity is designed to meet the educational needs of obstetricians and gynecologists, endocrinologists, primary care physicians, and other physicians who have an interest in female sexual dysfunction (FSD) and/or treat menopausal women.
Method of Participation |
This activity is comprised of one lecture presented in two formats to accommodate the bandwidth and learning preferences of the participant. The activity contains references for further study of this topic.
To receive a maximum of .75 AMA PRA Category 1 Credit(s)™ you should:
-
View the presentations in this CME activity and evaluate the content presented
Complete and submit the posttest, CME registration and activity evaluation forms
The estimated time to complete this activity, including review of the materials, is .75 hour(s).
Accreditation/Credit Designation |
back to top |
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Baylor College of Medicine designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ACCME accredited providers may issue credit to both U.S. and international physicians for any activity that has been designated for AMA PRA Category 1 Credit(s)™ in accordance with PRA requirements.
Term of Approval |
February 2008 through February 2009. Original release date: February 2005
Review |
back to top |
In January 2005, this continuing medical education activity was peer reviewed by Gloria A. Bachmann, MD, Professor, Departments of Medicine, and Obstetrics and Gynecology & Reproductive Sciences, Robert Wood Johnson School of Medicine – UMDNJ,
Dr. Bachmann is engaged in research for Johnson & Johnson, National Institutes of Health, Novartis Corporation, Pfizer Inc, and Wyeth Pharmaceuticals. She serves as a consultant for Solvay.
In order to ensure the continued scientific relevance of this enduring material, the content is reviewed annually. It was last reviewed for relevance and currency in February 2008 by Sheryl Kingsberg, PhD, Associate Professor, Departments of Reproductive Biology and Psychiatry, Case Western Reserve University School of Medicine,
Dr. Kingsberg is engaged in research for Boehringer Ingelheim, Organon, and Procter & Gamble. She has received honoraria from Organon and Procter & Gamble.
Program Director |
back to top |
Paula Amato, MD
Assistant Professor
Department of Obstetrics and
Dr. Amato has indicated that she has nothing to disclose.
Sandra Ann Carson, MD
Professor
Department of Obstetrics and
Dr. Carson has indicated that she has nothing to disclose.
Disclaimer |
This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.
Baylor College of Medicine makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site's terms and conditions of use including copyright and licensing restrictions.
Disclosure |
back to top |
The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the policies of the Accreditation Council for Continuing Medical Education and Baylor College of Medicine, the OCME is committed to the practice of disclosure by contributors of any significant financial interest or other relationship(s) with the manufacturer/provider of any commercial products/services that will be discussed, or with the commercial supporter(s), if any, of the activity.
Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.
In addition, contributors have been requested to use generic names for products (drugs/devices), and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CME activity evaluation candidly.
The following contributor(s) have reported financial or other relationship(s) with commercial entities whose products/services may be discussed in this activity:
Paula Amato, MD, has indicated that she has nothing to disclose.
Rosemary Basson, MB, BS, FRCP (UK), is a consultant for Pfizer and Solvay.
Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.
To comply with ACCME policies, Baylor College of Medicine requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
The following contributor in this activity has reported no discussion of "off-label" uses of pharmaceutical or medical device products in her presentation: Paula Amato, MD.
Rosemary Basson, MB, BS, FRCP (UK), has discussed the use of testosterone, estrogen, SERMS and tibolone for the treatment of female sexual dysfunction. The use of these treatments should be considered investigational.
Acknowledgement of Support |
This CME activity is supported by an educational grant from Procter & Gamble Pharmaceuticals, Inc.
| back to top |